Theresa Hahn

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4232468/publications.pdf

Version: 2024-02-01

163 papers	5,124 citations	94433 37 h-index	98798 67 g-index
166 all docs	166 docs citations	166 times ranked	5831 citing authors

#	Article	IF	Citations
1	Deciphering spatial genomic heterogeneity at a single cell resolution in multiple myeloma. Nature Communications, 2022, 13, 807.	12.8	29
2	Mass-Fix better predicts for PFS and OS than standard methods among multiple myeloma patients participating on the STAMINA trial (BMT CTN 0702 /07LT). Blood Cancer Journal, 2022, 12, 27.	6.2	19
3	CD319 (SLAMF7) an alternative marker for detecting plasma cells in the presence of daratumumab or elotuzumab. Cytometry Part B - Clinical Cytometry, 2021, 100, 497-508.	1.5	22
4	Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States. Cancer, 2021, 127, 609-618.	4.1	12
5	Serological Response to Vaccination after Autologous Transplantation for Multiple Myeloma Is Associated with Improved Progression-Free and Overall Survival. Transplantation and Cellular Therapy, 2021, 27, 245.e1-245.e8.	1.2	4
6	Neighborhood poverty and pediatric allogeneic hematopoietic cell transplantation outcomes: a CIBMTR analysis. Blood, 2021, 137, 556-568.	1.4	34
7	Optical Coherence Tomography for Quantifying Human Cutaneous Chronic Graft-versus-Host Disease. Transplantation and Cellular Therapy, 2021, 27, 271.e1-271.e8.	1.2	2
8	Genome-Wide Association Analyses Identify Variants in IRF4 Associated With Acute Myeloid Leukemia and Myelodysplastic Syndrome Susceptibility. Frontiers in Genetics, 2021, 12, 554948.	2.3	8
9	Novel genetic variants associated with mortality after unrelated donor allogeneic hematopoietic cell transplantation. EClinicalMedicine, 2021, 40, 101093.	7.1	8
10	Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphomaâ€“type Richter syndrome. Blood Advances, 2021, 5, 3528-3539.	5.2	24
11	Neither Donor nor Recipient Mitochondrial Haplotypes Are Associated with Unrelated Donor Transplant Outcomes: A Validation Study from the CIBMTR. Transplantation and Cellular Therapy, 2021, 27, 836.e1-836.e7.	1.2	0
12	Replicated Risk Index of Patient Functional Status Prior to Allogeneic Hematopoietic Cell Transplantation Predicts Healthcare Utilization and Survival. Transplantation and Cellular Therapy, 2021, 27, 875.e1-875.e9.	1.2	1
13	Association of Treatment Intensity With Survival in Older Patients With Hodgkin Lymphoma. JAMA Network Open, 2021, 4, e2128373.	5.9	6
14	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	12.8	17
15	Emerging trends of therapy related myeloid neoplasms following modern cancer therapeutics in the United States. Scientific Reports, 2021, 11, 23284.	3.3	3
16	Immune profiling in diffuse large B-cell lymphoma and mantle cell lymphoma patients treated with autologous hematopoietic cell transplant. Bone Marrow Transplantation, 2020, 55, 77-85.	2.4	4
17	Summary of the Third Annual Blood and Marrow Transplant Clinical Trials Network Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2020, 26, e7-e15.	2.0	16
18	Predictors of Loss to Follow-Up Among Pediatric and Adult Hematopoietic Cell Transplantation Survivors: A Report from the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2020, 26, 553-561.	2.0	13

#	Article	IF	Citations
19	Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Research and Treatment, 2020, 180, 187-195.	2.5	8
20	Identification of Neurotoxicity after Chimeric Antigen Receptor (CAR) T Cell Infusion without Deterioration in the Immune Effector Cell-Associated Encephalopathy (ICE) Score. Biology of Blood and Marrow Transplantation, 2020, 26, e271-e274.	2.0	13
21	Low-Level Cytomegalovirus Antigenemia Promotes Protective Cytomegalovirus Antigen-Specific T Cells after Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 2147-2154.	2.0	4
22	Association of donor IFNL4 genotype and non-relapse mortality after unrelated donor myeloablative haematopoietic stem-cell transplantation for acute leukaemia: a retrospective cohort study. Lancet Haematology,the, 2020, 7, e715-e723.	4.6	8
23	The Impact of Donor Type on Outcomes and Cost of Allogeneic Hematopoietic Cell Transplantation for Pediatric Leukemia: A Merged Center for International Blood and Marrow Transplant Research and Pediatric Health Information System Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 1747-1756.	2.0	7
24	Firstâ€line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)â€Medicare populationâ€based study. British Journal of Haematology, 2020, 190, 222-235.	2.5	10
25	Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplantation, 2019, 54, 497-507.	2.4	11
26	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. Biology of Blood and Marrow Transplantation, 2019, 25, 2086-2090.	2.0	42
27	Relationship between paid leave, financial burden, and patient-reported outcomes among employed patients who have undergone bone marrow transplantation. Quality of Life Research, 2019, 28, 1835-1847.	3.1	15
28	Validation of genetic associations with acute GVHD and nonrelapse mortality in DISCOVeRY-BMT. Blood Advances, 2019, 3, 2337-2341.	5.2	8
29	Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission. Blood Advances, 2019, 3, 1826-1836.	5.2	89
30	Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. Blood Advances, 2019, 3, 2512-2524.	5.2	7
31	Measuring serological response to vaccination before and after autologous hematopoietic cell transplantation in multiple myeloma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e44-e45.	0.4	0
32	Randomized controlled trial of individualized treatment summary and survivorship care plans for hematopoietic cell transplantation survivors. Haematologica, 2019, 104, 1084-1092.	3.5	46
33	Summary of the Second Annual BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling. Biology of Blood and Marrow Transplantation, 2019, 25, e89-e97.	2.0	12
34	gwasurvivr: an R package for genome-wide survival analysis. Bioinformatics, 2019, 35, 1968-1970.	4.1	72
35	Reduced-Intensity Conditioning with Fludarabine, Melphalan, and Total Body Irradiation for Allogeneic Hematopoietic Cell Transplantation: The Effect of Increasing Melphalan Dose on Underlying Disease and Toxicity. Biology of Blood and Marrow Transplantation, 2019, 25, 689-698.	2.0	9
36	Impact of conditioning regimen on peripheral blood hematopoietic cell transplant. World Journal of Clinical Oncology, 2019, 10, 86-97.	2.3	0

#	Article	IF	Citations
37	Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. Blood, 2018, 131, 2490-2499.	1.4	21
38	BPX-501 T cells interfere with minimal residual disease evaluation of B-cell acute lymphoblastic leukemia. Bone Marrow Transplantation, 2018, 53, 651-653.	2.4	2
39	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. Biology of Blood and Marrow Transplantation, 2018, 24, 1928-1935.	2.0	2
40	BMT CTN Myeloma Intergroup Workshop on Minimal Residual Disease and Immune Profiling: Summary and Recommendations from the Organizing Committee. Biology of Blood and Marrow Transplantation, 2018, 24, 641-648.	2.0	19
41	Financial Hardship after Hematopoietic Cell Transplantation: Lack of Impact on Survival. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 345-347.	2.5	6
42	Engaging Patients in Setting a Patient-Centered Outcomes Research Agenda in Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 1111-1118.	2.0	22
43	Impact of preâ€transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. Cancer, 2017, 123, 1828-1838.	4.1	73
44	Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Research and Treatment, 2017, 161, 501-513.	2.5	13
45	Ascertainment of Unmet Needs and Participation in Health Maintenance and Screening of Adult Hematopoietic Cell Transplantation Survivors Followed in a Formal Survivorship Program. Biology of Blood and Marrow Transplantation, 2017, 23, 1968-1973.	2.0	14
46	Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. Haematologica, 2017, 102, 1823-1832.	3.5	43
47	Replication and validation of genetic polymorphisms associated with survival after allogeneic blood or marrow transplant. Blood, 2017, 130, 1585-1596.	1.4	45
48	National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Research Methodology and Study Design Working Group Report. Biology of Blood and Marrow Transplantation, 2017, 23, 10-23.	2.0	20
49	Immune signatures associated with improved progression-free and overall survival for myeloma patients treated with AHSCT. Blood Advances, 2017, 1, 1056-1066.	5.2	40
50	Genetic association with B-cell acute lymphoblastic leukemia in allogeneic transplant patients differs by age and sex. Blood Advances, 2017, 1, 1717-1728.	5.2	15
51	Financial Burden and Patient-Reported Outcomes after Hematopoietic Cell Transplantation: Impact of Pre-Treatment Awareness of Transplant-Associated Costs. Blood, 2017, 130, 684-684.	1.4	1
52	Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. Blood, 2016, 128, 2450-2456.	1.4	32
53	Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk. Journal of the Neurological Sciences, 2016, 370, 13-17.	0.6	23
54	Financial Hardship and Patient-Reported Outcomes after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1504-1510.	2.0	63

#	Article	IF	Citations
55	Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. Biology of Blood and Marrow Transplantation, 2016, 22, 744-751.	2.0	41
56	Comparing Outcomes with Bone Marrow or Peripheral Blood Stem Cells as Graft Source for Matched Sibling Transplants in Severe Aplastic Anemia across Different Economic Regions. Biology of Blood and Marrow Transplantation, 2016, 22, 932-940.	2.0	43
57	Evolution of Multiparametric Flow Cytometry Testing for Minimal Residual Disease Assessment in Multiple Myeloma and Its Impact on Clinical Outcomes: A Single Institution Experience. Blood, 2016, 128, 2274-2274.	1.4	1
58	Replication of Candidate SNP Survival Analyses and Gene-Based Tests of Association with Survival Outcomes after an Unrelated Donor Blood or Marrow Transplant: Results from the Discovery-BMT Study. Blood, 2016, 128, 71-71.	1.4	0
59	Exome Array Analyses Identify New Genes Influencing Survival Outcomes after HLA-Matched Unrelated Donor Blood and Marrow Transplantation. Blood, 2016, 128, 518-518.	1.4	0
60	Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A CIBMTR Analysis. Blood, 2016, 128, 842-842.	1.4	0
61	Role of Donor Source on Clinical Outcomes and Inpatient Resource Utilization for Hematopoietic Cell Transplantation in Children with Acute Leukemia. Blood, 2016, 128, 3575-3575.	1.4	0
62	Identification of Immune Phenotypes Associated with Improved Progression Free and Overall Survival for Patients with Multiple Myeloma Treated with Autologous Hematopoietic Cell Transplantation. Blood, 2016, 128, 3454-3454.	1.4	0
63	Exome Array Analyses Identify Low-Frequency Germline Variants Associated with Increased Risk of AML in a HLA-Matched Unrelated Donor Blood and Marrow Transplant Population. Blood, 2016, 128, 42-42.	1.4	0
64	Prospective Assessment of Familial Financial Hardship after Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, S72.	2.0	4
65	Impact of Race on Graft-Versus-Host Disease Rates after HLA-Matched Sibling Bone Marrow or Peripheral Blood Hematopoietic Cell Transplantation: Comparison of North American Caucasian Versus Japanese Populations. Biology of Blood and Marrow Transplantation, 2015, 21, S34-S35.	2.0	1
66	Identification and Utilization of Donor and Recipient Genetic Variants to Predict Survival After HCT: Are We Ready for Primetime?. Current Hematologic Malignancy Reports, 2015, 10, 45-58.	2.3	11
67	Population-Based Analysis of Hematologic Malignancy Referrals to a Comprehensive Cancer Center, Referrals for Blood and Marrow Transplantation, and Participation in Clinical Trial, Survey, and Biospecimen Research by Race. Biology of Blood and Marrow Transplantation, 2015, 21, 1488-1494.	2.0	6
68	Granzyme Bâ€“Mediated Activation-Induced Death of CD4+ T Cells Inhibits Murine Acute Graft-versus-Host Disease. Journal of Immunology, 2015, 195, 4514-4523.	0.8	21
69	Establishment of Definitions and Review Process for Consistent Adjudication of Cause-specific Mortality after Allogeneic Unrelated-donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 1679-1686.	2.0	37
70	The Impact of Pre-Transplant Depression on Outcomes of Allogeneic and Autologous Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 265-265.	1.4	3
71	Effect of Immune Reconstitution on Survival after Autologous Hematopoietic Cell Transplant for B-Cell Non-Hodgkin Lymphoma. Blood, 2015, 126, 3173-3173.	1.4	1
72	A Study of Predictors of Clinical Outcomes and Healthcare Utilization in Children with Sickle Cell Disease Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 528-528.	1.4	4

#	Article	IF	Citations
73	Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study). Blood, 2015, 126, 61-61.	1.4	7
74	Evidence for Heterogeneous Genetic Associations with Acute Lymphoblastic Leukemia (ALL) By Cytogenetics and Sex in High-Risk Patients Treated with Matched Unrelated Donor Allogeneic Blood or Marrow Transplant (URD-BMT). Blood, 2015, 126, 2621-2621.	1.4	5
75	Genome-Wide Association Study of Overall and Progression-Free Survival after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (DISCOVeRY-BMT study). Blood, 2015, 126, 397-397.	1.4	1
76	Higher Total Nucleated Cell Dose, but Not CD3+, 4+, 8+, or 34+ Cell Dose, Is Associated with Better Overall and Progression-Free Survival after Allogeneic Peripheral Blood Hematopoietic Cell Transplantation (AlloPBHCT) with TBI-Based Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2014, 20, S30-S31.	2.0	0
77	Patterns of Referral for, and Utilization of, Blood and Marrow Transplantation (BMT) By Race. Biology of Blood and Marrow Transplantation, 2014, 20, S110-S111.	2.0	0
78	Value of a Consensus Panel to Adjudicate Cause-Specific Mortality after Unrelated Donor Allogeneic Hematopoietic Cell Transplantation (URD-HCT) for Use As the Primary Endpoint in a Genome-Wide Association Study (GWAS). Biology of Blood and Marrow Transplantation, 2014, 20, S35-S36.	2.0	1
79	Fludarabine and cyclophosphamide provides a nonmyeloablative alternative conditioning regimen with low transplant-related mortality and control of high risk disease. Leukemia Research Reports, 2014, 3, 28-31.	0.4	0
80	Early versus Late Preemptive Allogeneic Hematopoietic Cell Transplantation for Relapsed or Refractory Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 1369-1374.	2.0	5
81	Do Hematopoietic Cell Transplant Patients Treated on a Clinical Trial Do Better? Comparison of Characteristics and Outcomes of Patients Enrolled Versus Not Enrolled on Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0201 Trial. Blood, 2014, 124, 209-209.	1.4	0
82	Trends in Use of and Survival after Autologous Hematopoietic Cell Transplantation in North America, 1995-2005: Significant Improvement in Survival for Lymphoma and Myeloma during a Period of Increasing Recipient Age. Biology of Blood and Marrow Transplantation, 2013, 19, 1116-1123.	2.0	104
83	Unrelated Donor Allogeneic Hematopoietic Cell Transplantation Is Underused as a Curative Therapy in Eligible Patients from the United States. Biology of Blood and Marrow Transplantation, 2013, 19, 1459-1464.	2.0	25
84	Prevalence of Hematopoietic Cell Transplant Survivors in the United States. Biology of Blood and Marrow Transplantation, 2013, 19, 1498-1501.	2.0	210
85	Simplified Validated Prognostic Model for Progression-Free Survival after Autologous Transplantation for Hodgkin Lymphomaâˆ—. Biology of Blood and Marrow Transplantation, 2013, 19, 1740-1744.	2.0	52
86	Significant Improvement in Survival After Allogeneic Hematopoietic Cell Transplantation During a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors. Journal of Clinical Oncology, 2013, 31, 2437-2449.	1.6	223
87	Autologous hematopoietic stem cell transplantation and maintenance therapy for multiple myeloma. International Journal of Hematologic Oncology, 2013, 2, 71-83.	1.6	3
88	Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients. Hematology American Society of Hematology Education Program, 2013, 2013, 496-503.	2.5	6
89	Analysis Of Immune Cell Populations Before and After Autologous Hematopoietic Stem Cell Transplant For Multiple Myeloma: Association With Early Recovery Of Absolute Lymphocyte Count and Progression-Free Survival. Blood, 2013, 122, 3348-3348.	1.4	0
90	HLA DR15 Antigen Status Does Not Impact Graft-versus-Host Disease or Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Biology of Blood and Marrow Transplantation, 2012, 18, 1302-1308.	2.0	15

#	Article	IF	Citations
91	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 18-36.e6.	2.0	58
92	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Update of the 2006 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 16-17.	2.0	18
93	Outcomes of Allogeneic Hematopoietic Cell Transplantation for Adolescent and Young Adults Compared with Children and Older Adults with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2012, 18, 861-873.	2.0	53
94	Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 505-522.	2.0	96
95	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Pediatric Acute Lymphoblastic Leukemia: Update of the 2005 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2012, 18, 979-981.	2.0	32
96	Transplantation for Autoimmune Diseases in North and South America: A Report of the Center for International Blood and Marrow Transplant Research. Biology of Blood and Marrow Transplantation, 2012, 18, 1471-1478.	2.0	62
97	Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood, 2012, 119, 296-307.	1.4	559
98	Short Course of Levofloxacin During Neutropenia Prevents Early and Late Bacteremia Episodes After Allogeneic Blood and Marrow Transplantation (alloBMT). Blood, 2012, 120, 4141-4141.	1.4	0
99	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Diffuse Large B Cell Lymphoma: Update of the 2001 Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2011, 17, 20-47.e30.	2.0	91
100	Common Genetic Variants Are Associated with Accelerated Bone Mineral Density Loss after Hematopoietic Cell Transplantation. PLoS ONE, 2011, 6, e25940.	2.5	6
101	Self-determinism: alloBMT for AML. Blood, 2011, 117, 2080-2081.	1.4	3
102	Managing cardiac amyloidosis: Auto or allotransplant?. American Journal of Hematology, 2011, 86, 885-886.	4.1	0
103	A CIBMTR Prognostic Model for Progression-Free Survival (PFS) After Autologous Hematopoietic Cell Transplantation (AHCT) for Relapsed or Refractory Hodgkin Lymphoma (HL). Blood, 2011, 118, 499-499.	1.4	14
104	Fludarabine, Melphalan and Low Dose Total Body Irradiation for Reduced Intensity Conditioning (RIC) Prior to Allogeneic Hematopoietic Cell Transplantation (AlloHCT). Blood, 2011, 118, 4570-4570.	1.4	0
105	Micro Dose Methotrexate (MTX) Is Equivalent to Full Dose MTX and Superior to No MTX for Acute Graft-Versus-Host Disease Prophylaxis. Blood, 2011, 118, 3038-3038.	1.4	0
106	Optimizing the Timing of Allogeneic Blood or Marrow Transplantation (BMT) in a Prospective Cohort of Relapsed or Refractory Acute Myeloid Leukemia (AML). Blood, 2011, 118, 3096-3096.	1.4	4
107	HLA DR15 Antigen Status Does Not Impact Graft-Versus-Host Disease or Disease-Free Survival in HLA-Matched Sibling Transplantation for Hematologic Malignancies. Blood, 2011, 118, 3094-3094.	1.4	0
108	Effect of Age on Outcome of Reduced-Intensity Hematopoietic Cell Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission or With Myelodysplastic Syndrome. Journal of Clinical Oncology, 2010, 28, 1878-1887.	1.6	459

#	Article	IF	Citations
109	Outcomes of Hematologic Malignancies after Unrelated Donor Hematopoietic Cell Transplantation According to Place of Residence. Biology of Blood and Marrow Transplantation, 2010, 16, 368-375.	2.0	26
110	A Deletion Polymorphism in Glutathione-S-Transferase Mu (GSTM1) and/or Theta (GSTT1) Is Associated with an Increased Risk of Toxicity after Autologous Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 801-808.	2.0	30
111	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Treatment of Follicular Lymphoma: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2010, 16, 443-468.	2.0	60
112	Accelerated Bone Mineral Density Loss Occurs with Similar Incidence and Severity, But with Different Risk Factors, after Autologous versus Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2010, 16, 1130-1137.	2.0	26
113	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults. Biology of Blood and Marrow Transplantation, 2010, 16, 1442-1450.	2.0	64
114	Significant Improvement In Day 100 and 1-Year Overall Survival In Patients Who Underwent Myeloablative Allogeneic Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 3509-3509.	1.4	0
115	Risk-Factors for Acute Graft-Versus-Host Disease and Survival After Hematopoietic Cell Transplantation From Siblings and Unrelated Donors â€“ An Analysis of the CIBMTR. Blood, 2010, 116, 897-897.	1.4	0
116	Significant Improvement In Overall Survival In Patients Who Underwent Autologous Hematopoietic Cell Transplant In the US or Canada Between 1994 and 2005. Blood, 2010, 116, 2389-2389.	1.4	0
117	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Myelodysplastic Syndromes: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2009, 15, 137-172.	2.0	76
118	A Comparison of Measured Creatinine Clearance versus Calculated Glomerular Filtration Rate for Assessment of Renal Function before Autologous and Allogeneic BMT. Biology of Blood and Marrow Transplantation, 2009, 15, 574-579.	2.0	21
119	Seeing What's Out of Sight: Wireless Capsule Endoscopy's Unique Ability to Visualize and Accurately Assess the Severity of Gastrointestinal Graft-versus-Host-Disease. Biology of Blood and Marrow Transplantation, 2009, 15, 643-648.	2.0	25
120	Methodology for Updating Published Evidence-Based Reviews Evaluating the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: A Policy Statement by the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 761-762.	2.0	9
121	Fatal Hyperacute Graft-versus-Host Disease following Denileukin Diftitox Treatment for Recurrent T Cell Lymphoma after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 887-890.	2.0	1
122	Race and Socioeconomic Status Influence Outcomes of Unrelated Donor Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2009, 15, 1543-1554.	2.0	135
123	The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation. Blood, 2009, 113, 3110-3118.	1.4	147
124	Diverse Roles of Hepatocyte Growth Factor (HGF) in Normal Karyotype Acute Myeloid Leukemia (AML).. Blood, 2009, 114, 3107-3107.	1.4	0
125	Comparison of Prognostic Models for Autologous Hematopoietic Stem Cell Transplantation (AHCT) for Relapsed Hodgkin Lymphoma.. Blood, 2009, 114, 1215-1215.	1.4	0
126	Pharmacokinetics of Mycophenolic Mofetil and Metabolites in Allogeneic Transplant: Determination of Maximum Dose Schedule and Route of Administration.. Blood, 2009, 114, 2276-2276.	1.4	0

#	Article	IF	Citations
127	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2008, 14, 137-180.	2.0	90
128	Risk Factors for Acute Graft-Versus-Host Disease After Human Leukocyte Antigenâ€"Identical Sibling Transplants for Adults With Leukemia. Journal of Clinical Oncology, 2008, 26, 5728-5734.	1.6	159
129	Human leukocyte antigen DR4 is associated with inferior progression-free survival following allogeneic hematopoietic stem cell transplantation for lymphoid malignancies. Leukemia and Lymphoma, 2008, 49, 1494-1500.	1.3	2
130	The Effects of Rituximab Added to Front-Line or Salvage Chemotherapy in Diffuse Large B-Cell Lymphoma (DLBCL) Undergoing High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT).. Blood, 2008, 112, 1138-1138.	1.4	1
131	BuCy Provides Equivalent Outcomes to VCyTBI as Conditioning Prior to Auto-SCT in Patients with Relapsed/Refractory NHL and Is a Valuable Option in Older (â‰¥60 years) Patients.. Blood, 2008, 112, 2176-2176.	1.4	4
132	Gemtuzumab Ozogamicin (GO) and Continuous Infusion Cytarabine (ARA-C) for Relapsed/Refractory Acute Myeloid Leukemia (AML) Prior to Allogeneic Stem Cell Transplantation (SCT).. Blood, 2008, 112, 952-952.	1.4	0
133	Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML) in Adults. Blood, 2008, 112, 51-51.	1.4	0
134	Clinical and Genetic Factors Underlying Acute Bone Mineral Density Loss by 100 Days after Blood and Marrow Transplantation: A Potential Early Regimen-Related Complication. Blood, 2008, 112, 52-52.	1.4	0
135	Excess diagnosis of non-Hodgkin's lymphoma during spring in the USA. Leukemia and Lymphoma, 2007, 48, 357-366.	1.3	8
136	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myeloid Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2007, 13, 1-25.	2.0	90
137	HLA DR15 and Immunobiologic Outcomes. Biology of Blood and Marrow Transplantation, 2007, 13, 371.	2.0	2
138	Ganciclovir Inhibits Lymphocyte Proliferation by Impairing DNA Synthesis. Biology of Blood and Marrow Transplantation, 2007, 13, 765-770.	2.0	74
139	Graft-Versus-Leukemia Effect Is Equivalent in Recipients of Matched Sibling and Matched Unrelated Donor Conventional Hematopoietic Cell Transplant.. Blood, 2007, 110, 3049-3049.	1.4	1
140	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Deletion Polymorphisms Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. Blood, 2007, 110, 1982-1982.	1.4	1
141	Wireless Capsule Endoscopy (WCE) Is an Important Diagnostic and Management Tool of Gastrointestinal (GI) Acute and Chronic Graft Versus Host Disease (GVHD) after Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) and Identifies Gastroparesis as a Prominent Complication of GI GVHD.. Blood, 2007, 110, 2985-2985.	1.4	0
142	Risk Factors for Acute Graft-Versus-Host Disease (GvHD) after Related Donor HLA-Matched Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) for Adult Leukemia: Identification of Modifiable and Non-Modifiable Factors. A CIBMTR Study.. Blood, 2007, 110, 1069-1069.	1.4	0
143	Outcomes of Relapsed/Refractory B-Cell Lymphoma Is Improved by Salvage Chemotherapy Consisting of Two to Three Cycles of Dexamethasone (D), High Dose Ara-C (HA) and Carboplatin (DHAC) with or without Rituximab (R) Followed by Autologous Stem Cell Transplantation.. Blood, 2007, 110, 5130-5130.	1.4	0
144	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Adults: An Evidence-based Review. Biology of Blood and Marrow Transplantation, 2006, 12, 1-30.	2.0	109

#	Article	IF	Citations
145	Human leukocyte antigen (HLA) DR15 is associated with reduced incidence of acute GVHD in HLA-matched allogeneic transplantation but does not impact chronic GVHD incidence. Blood, 2006, 107, 1970-1973.	1.4	26
146	Effect of Bone Marrow Hypoplasia Secondary to Reinduction Therapy for Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) on Outcomes after Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 3033-3033.	1.4	0
147	Glutathione-S-Transferase M1 (GSTM1) and T1 (GSTT1) Single Nucleotide Polymorphisms (SNPs) Predict Regimen-Related Toxicity after Autologous and Allogeneic Blood and Marrow Transplantation (BMT).. Blood, 2006, 108, 47-47.	1.4	0
148	Analysis of Donor Age and Absolute Lymphocyte Count Recovery as Prognostic Indicators of Survival after Allogeneic Blood or Marrow Transplantation.. Blood, 2006, 108, 5252-5252.	1.4	0
149	A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplantation, 2005, 35, 557-566.	2.4	27
150	Invasive filamentous fungal infections in allogeneic hematopoietic stem cell transplant recipients after recovery from neutropenia: Clinical, radiologic, and pathologic characteristics. Mycopathologia, 2005, 159, 181-188.	3.1	73
151	Arterial thrombosis in four patients treated with thalidomide. Leukemia and Lymphoma, 2005, 46, 239-242.	1.3	47
152	Long-Term Use of Oral Beclomethasone Dipropionate for the Treatment of Gastrointestinal Graft-versus-Host Disease. Biology of Blood and Marrow Transplantation, 2005, 11, 587-592.	2.0	30
153	The Evolution of the Evidence-Based Review: Evaluating the Science Enhances the Art of Medicineâ€"Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biology of Blood and Marrow Transplantation, 2005, 11, 819-822.	2.0	19
154	The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Lymphoblastic Leukemia in Children: An Evidence-Based Review. Biology of Blood and Marrow Transplantation, 2005, 11, 823-861.	2.0	67
155	High Frequency and Early Onset of Bone Mineral Density Loss Following Allogeneic Stem Cell Transplantation.. Blood, 2005, 106, 2011-2011.	1.4	6
156	Long-Term Survival With Allogeneic Stem Cell Transplant and Donor Lymphocyte Infusion Following Salvage Therapy with Anti-CD52 Monoclonal Antibody (Campath) in a Patient with Î±/Î² Hepatosplenic T-Cell Non-Hodgkin's Lymphoma. Leukemia and Lymphoma, 2004, 45, 1673-1675.	1.3	31
157	Histopathologic verification of acute leukemia (AL) in a cohort of 463 post-Chernobyl patients from Belarus, Russia and Ukraine. Leukemia Research, 2004, 28, 1273-1280.	0.8	5
158	Thrombotic Microangiopathy after Allogeneic Blood and Marrow Transplantation Is Associated with Dose-Intensive Myeloablative Conditioning Regimens, Unrelated Donor, and Methylprednisolone T-Cell Depletion. Transplantation, 2004, 78, 1515-1522.	1.0	36
159	Human Leukocyte Antigen (HLA) DR15 Is Associated with Reduced Incidence of Acute GvHD in HLA-Matched Allogeneic HSCT but Does Not Impact Survival.. Blood, 2004, 104, 3319-3319.	1.4	0
160	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: An evidence-based review. Biology of Blood and Marrow Transplantation, 2003, 9, 4-37.	2.0	85
161	Efficacy of High-Efficiency Particulate Air Filtration in Preventing Aspergillosis in Immunocompromised Patients With Hematologic Malignancies. Infection Control and Hospital Epidemiology, 2002, 23, 525-531.	1.8	122
162	The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: An evidence-based review. Biology of Blood and Marrow Transplantation, 2001, 7, 308-331.	2.0	52

#	Article	IF	Citations
163	Evidence-Based Reviews and the Role of Blood and Marrow Transplantation in the Treatment of Selected Diseases: An ASBMT Policy Statement. Biology of Blood and Marrow Transplantation, 2000, 6, 523-525.	2.0	9